Vbi Vaccines Inc CS (VBIV) |
|
3.07 0.17 (5.86%)
|
07-29 04:34 |
|
Open: |
2.86 |
Pre. Close: |
2.9 |
|
High:
|
3.085 |
Low:
|
2.86 |
|
Volume:
|
2,025,577 |
Market Cap:
|
780M |
|
|
|
|
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.097 - 3.118 |
3.118 - 3.136 |
|
Low:
|
2.812 - 2.837 |
2.837 - 2.859 |
|
Close:
|
3.029 - 3.071 |
3.071 - 3.108 |
|
Technical analysis |
as of: 2021-07-28 4:47:49 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 4.37 One year: 5.03 |
| Support: |
Support1: 2.83 Support2: 2.35 |
| Resistance: |
Resistance1: 3.74 Resistance2: 4.31 |
| Pivot: |
3.05  |
| Moving Average: |
MA(5): 2.99 MA(20): 3.11
MA(100): 3.23 MA(250): 3.24 |
| MACD: |
MACD(12,26): -0.14 Signal(9): -0.14 |
| Stochastic oscillator: |
%K(14,3): 29.85 %D(3): 25.23 |
| RSI: |
RSI(14): 44.06 |
| 52-week: |
High: 5.22 Low: 2.07 Change(%): -19.2 |
| Average Vol(K): |
3-Month: 323170 10-Days: 202810 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.VBIV has closed below upper band by 44.6%. Bollinger Bands are 52.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to VBIV's normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Wed, 31 Dec 1969
Wed, 31 Dec 1969
Wed, 31 Dec 1969
Wed, 31 Dec 1969
Wed, 31 Dec 1969
Wed, 31 Dec 1969
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
254 |
| Shares Float (M) |
177 |
|
% Held by Insiders
|
3.27 |
|
% Held by Institutions
|
53.23 |
|
Shares Short (K)
|
35,220 |
|
Shares Short P. Month (K)
|
37,710 |
Stock Financials |
|
EPS
|
-0.235 |
|
EPS Est This Year
|
-0.890 |
|
EPS Est Next Year
|
-1.010 |
|
Book Value (p.s.)
|
0.710 |
|
Profit Margin
|
|
|
Operating Margin
|
-5269.38 |
|
Return on Assets (ttm)
|
-18.9 |
|
Return on Equity (ttm)
|
-43.6 |
|
Qtrly Rev. Growth
|
-27.5 |
|
Gross Profit (p.s.)
|
-0.032 |
|
Sales Per Share
|
0.004 |
|
EBITDA (p.s.)
|
-0.190 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-46 |
|
Levered Free Cash Flow (M)
|
-26 |
Stock Valuations |
|
PE Ratio
|
-13.06 |
|
PEG Ratio
|
|
|
Price to Book value
|
4.32 |
|
Price to Sales
|
824.07 |
|
Price to Cash Flow
|
-16.95 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
2012-12-27 |
|
Ex-Dividend Date
|
2012-02-04 |
|
7 Binary Options
|
|
Your Ad Here
|
|
